img.header.lexi.jpg

INNOVATIONS / LEXI®

INEX IS ONE OF A HANDFUL OF COMPANIES IN THE WORLD THAT HAS SUCCESSFULLY PATENTED THE METHODOLOGY OF THE ISOLATION OF FETAL CELLS IN MATERNAL BLOOD. 

A STUDY FOUND THAT 72% OF WOMEN WOULD BE INTERESTED IN A NON INVASIVE PRENATAL DIAGNOSTIC TEST, AND THE SAFETY OF THEIR FETUS WAS THE SINGLE MOST IMPORTANT FACTOR IN CONSIDERING PRENATAL DIAGNOSIS1

Fetal cells in maternal blood represent the Holy Grail of prenatal diagnosis. The major challenge has been isolation of these cells from maternal blood owing to their rarity. Major advances have been made by INEX team in the field of Non Invasive Prenatal Diagnosis (NIPD), to isolate, recognise and analyse the fetal cells derived from maternal blood.

Current Non-Invasive Prenatal Test (NIPT) utilise fragmented circulating cell-free fetal DNA (cffDNA) in pregnant women, 
and makes inferences from the maternal blood.

Source:
1. Noninvasive Prenatal Diagnosis: Pregnant Women’s Interest and Expected Uptake Reana Tischler,1 Louanne Hudgins,2 Yair J. Blumenfeld,3 Henry T. Greely,1,4,5 and Kelly E. Ormond1,5

img.lexi.png

 INEX has been working with National University of Singapore (NUS) and Agency of Science Technology and Research (A*STAR, Singapore) to develop LEXI®, and is one of a handful of companies in the world that has successfully patented the methodology of the isolation of fetal cells in maternal blood globally.